NCT04901299: Fulvestrant + Neratinib In Breast Cancer

Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: HER2
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients with triple negative breast cancer are eligible only if their tumors express “ER or PR low positive” (less than 10%) as per updated ASCO/CAP 2020 guidelines
Exclusions: Patients treated with more than three prior chemotherapy regimens; Patients who have received prior neratinib or any anti-HER2 therapy for metastatic disease; Patients with progressive symptomatic unstable CNS metastatic disease that requires treatment – see trial for details

Comments are closed.

Up ↑